Completed PHASE1 INTERVENTIONAL 1-arm NCT02597400

Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM

A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Glucokinase (GK) Activator HMS5552 and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Sponsor: Hua Medicine Limited

Conditions Type 2 Diabetes Mellitus

Interventions HMS5552 Metformin

Updated 6 times since 2017 Last updated: Feb 16, 2016 Started: Oct 31, 2015 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Type 2 Diabetes Mellitus and is currently completed. Hua Medicine Limited leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hua Medicine Limited

Data source: Hua Medicine Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hackensack, United States